About Us
About Yu-Jet
Yu-Jet Co., Ltd. is a Taiwan-based biopharmaceutical company dedicated to the development of treatments for rare diseases.
The company integrates drug formulation development, clinical research, and Clinical Decision Support System (CDSS) technologies, building on three pillars — Drug R&D × Precision Medicine × Clinical Application — to bring local innovations to the global stage.
- Mission： Patient-centric innovation to make rare disease treatments more accessible and affordable.
- Vision： To build a globally recognized precision medicine brand for rare diseases originating from Taiwan.
Pipeline & Products
News
| 1. | 2025.09 | The Muscle Health Recognition System participated in the 2025 AI Healthcare Innovation Competition and advanced to the finals. | |
| 2. | 2025.03 | YJ-DR202 successfully obtained a U.S. invention patent approval, marking a new milestone in Yu-Jet’s global expansion. | |
| 3. | 2025.01 | YJ-DI304 won hospital tender approval and entered clinical sales channels. | |
| 4. | 2024.10 | YJ-DR202 received the National Brand Yushan Award – Best Product Category, recognizing Yu-Jet’s innovation and quality in rare-disease drug development. | |
| 5. | 2024.03 | Signed an exclusive distribution agreement for YJ-DI303 (Fabry Disease therapy) in Taiwan, expanding Yu-Jet’s rare-disease portfolio. | |
| 6. | 2023.10 | YJ-DR202 granted Orphan Drug Designation (ODD) by TFDA. | |
| 7. | 2023.10 | L-Arginine Capsule listed in the Rare Disease Reimbursement Program. | |
| 8. | 2023.07 | YJ-DR202 obtained Taiwan invention patent approval. | |
| 9. | 2023.06 | YJ-DR202 clinical trial final report approved by TFDA, marking a key milestone in Yu-Jet’s rare-disease drug program. | |
| 10. | 2022.08 | Signed exclusive Taiwan distribution agreement for YJ-DI302 (Epilepsy treatment), launching the commercialization phase. |
Contact Us
Yu-Jet Co., Ltd.
Address
5F., No. 67, Changchun Rd., Zhongshan Dist., Taipei City 104612, Taiwan (R.O.C.)
Tel
02-2563-1321
Fax
02-2564-1866
